| Keyword | CPC | PCC | Volume | Score | Length of keyword |
|---|---|---|---|---|---|
| sacituzumab govitecan study | 1.3 | 0.9 | 173 | 87 | 27 |
| sacituzumab | 1.73 | 0.4 | 4537 | 19 | 11 |
| govitecan | 1.59 | 1 | 7815 | 16 | 9 |
| study | 0.92 | 0.2 | 4230 | 99 | 5 |
| Keyword | CPC | PCC | Volume | Score |
|---|---|---|---|---|
| sacituzumab govitecan synthesis | 0.67 | 0.8 | 4087 | 57 |
| sacituzumab govitecan ema | 0.24 | 0.7 | 2591 | 73 |
| sacituzumab govitecan structure | 0.01 | 0.8 | 9528 | 95 |
| sacituzumab govitecan eviq | 0.23 | 1 | 8045 | 35 |
| sacituzumab govitecan extravasation | 1.96 | 0.7 | 4835 | 75 |
| sacituzumab govitecan seagen | 1.16 | 0.1 | 4104 | 91 |
| sacituzumab govitecan erfahrungen | 0.96 | 0.4 | 3561 | 44 |
| sacituzumab govitecan emc | 0.35 | 0.4 | 8215 | 20 |
| sacituzumab govitecan sequence | 0.03 | 0.9 | 599 | 47 |
| sacituzumab govitecan efficacia | 1.22 | 0.9 | 6712 | 41 |
| sacituzumab govitecan effetti collaterali | 0.68 | 0.7 | 1954 | 20 |
| sacituzumab govitecan epar | 1.76 | 0.4 | 4337 | 49 |
| sacituzumab govitecan effets secondaires | 1.35 | 0.5 | 1968 | 75 |
| sacituzumab govitecan manufacturer | 0.84 | 0.4 | 636 | 88 |
| sacituzumab govitecan macmillan | 0.44 | 0.8 | 2943 | 98 |
| sacituzumab govitecan mammakarzinom | 0.67 | 0.7 | 6395 | 13 |
| sacituzumab govitecan and berzosertib | 1.77 | 0.8 | 4200 | 95 |
| sacituzumab govitecan mechanism of action | 1.35 | 0.8 | 4309 | 11 |
| sacituzumab govitecan ascent | 0.04 | 0.8 | 9790 | 46 |
